Stem Cell Therapy for Lymphoma Treatment
Discover how stem cell therapy as a treatment for lymphoma can offer hope and advanced healing options for patients. Explore the transformative approach.
Beam’s Breakthrough: Revolutionizing Genetic Medicine?
Beam Therapeutics Inc., a leading biotechnology company specializing in precision genetic medicines through base editing, has recently made a significant announcement. In August, the company initiated treatment for its first patient with BEAM-201, a quadruplex-edited allogeneic CAR-T cell investigational therapy. This therapy is currently under evaluation in a Phase 1/2 clinical trial aimed at treating […]
Be The Match Foundation’s Triumph: Over $327,000 Raised at the Annual Los Angeles Soirée
In a remarkable display of philanthropy and community spirit, the Be The Match Foundation® celebrated its annual Los Angeles Soirée on August 11 at the Skirball Cultural Center. This event, dedicated to supporting patients battling life-threatening blood cancers and disorders, witnessed an astounding collection of over $327,000 in a single night. A Night of Hope […]
Clinical Applications of Hematopoietic Stem Cells in Blood Cell Disorders
Welcome, dear readers, to our exploration of the fascinating world of stem cells. Today, we’re diving deep into a specific type of stem cell, known as the hematopoietic stem cell. Picture these cells as the master builders of our blood system, the architects that design and construct the various types of cells that flow through […]
Revolution in Oncology: How Stem Cell Transplants are Changing the Game in Cancer Treatment
Welcome, dear reader! It’s a pleasure to have you here as we embark on an enlightening journey into the world of stem cell transplants in oncology. This article is designed for those who are keen to learn more about cancer treatment options or are simply intrigued by the latest advancements in medical science. Consider this […]
How These College Interns Are Saving Lives and Breaking Records with Be The Match
Be The Match, the organization behind the world’s most diverse registry of blood stem cell and marrow donors, announced that the William G. Pomeroy Foundation has granted them an additional $300,000. This generous contribution will allow the organization to further diversify the Be The Match Registry by expanding its presence at historically Black colleges and […]
Be The Match Advocates Garner $420,000+ at 2023 NY Gala for Life-Saving Blood Stem Cell Transplants
On May 4, 2023, Be The Match Foundation® hosted its annual New York Gala at the Cipriani on Broadway to raise funding for patient assistance grants, research to improve transplant outcomes, and diversification of the Be The Match Registry®. In 2022, the foundation provided $6.1 million in grants to 2,320 patients and families in need […]
Unite to Fight Blood Cancer: The Vital Role of Ethnic Minority Stem Cell Donors
In this video, Antoinette, a mother of two suffering from incurable blood cancer, shares her struggle to find a stem cell donor for nine years. She has undergone eight different types of chemotherapy, and her myeloma has spread to her spine, causing 13 spinal fractures. While a stem cell transplant won’t cure her, it would […]
Autologous Stem Cell Transplant: Benefits & Risks
An autologous stem cell transplant is a medical procedure that involves taking stem cells from the body of a person, processing and storing them, and then reinfusing them back into the same person’s body. This procedure has been used to treat various kinds of illnesses, including blood cancer and other diseases of the immune system. […]
Angiocrine Bioscience Announces it has been awarded a $15M Grant from the California Institute for Regenerative Medicine for AB-205 Phase 3 Clinical Trial
SAN DIEGO, Dec. 19, 2022 /PRNewswire/ — Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company today announced that the California Institute for Regeneration Medicine (CIRM) has approved investing $15M in the Phase 3 registration study AB-205-301 (E-CELERATE), a multi-center, randomized, double-blind, placebo-controlled study of AB-205 in adults with lymphoma undergoing high-dose chemotherapy (HDT) and autologous hematopoietic cell transplantation (AHCT). AB-205 […]